DK0553392T4 - Fremgangsmåde til opnåelse af stabiliserede formuleringer med acrylpolymerovertræk til kontrolleret frigivelse - Google Patents

Fremgangsmåde til opnåelse af stabiliserede formuleringer med acrylpolymerovertræk til kontrolleret frigivelse

Info

Publication number
DK0553392T4
DK0553392T4 DK92113236T DK92113236T DK0553392T4 DK 0553392 T4 DK0553392 T4 DK 0553392T4 DK 92113236 T DK92113236 T DK 92113236T DK 92113236 T DK92113236 T DK 92113236T DK 0553392 T4 DK0553392 T4 DK 0553392T4
Authority
DK
Denmark
Prior art keywords
acrylic polymer
controlled release
polymer coated
coated formulations
obtaining controlled
Prior art date
Application number
DK92113236T
Other languages
English (en)
Other versions
DK0553392T3 (da
Inventor
Benjamin Oshlack
Mark Chasin
Frank Pedi Jr
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25245664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0553392(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK0553392T3 publication Critical patent/DK0553392T3/da
Publication of DK0553392T4 publication Critical patent/DK0553392T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Moulds For Moulding Plastics Or The Like (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK92113236T 1992-01-27 1992-08-03 Fremgangsmåde til opnåelse af stabiliserede formuleringer med acrylpolymerovertræk til kontrolleret frigivelse DK0553392T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/826,084 US5286493A (en) 1992-01-27 1992-01-27 Stabilized controlled release formulations having acrylic polymer coating

Publications (2)

Publication Number Publication Date
DK0553392T3 DK0553392T3 (da) 2000-03-06
DK0553392T4 true DK0553392T4 (da) 2008-03-03

Family

ID=25245664

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92113236T DK0553392T4 (da) 1992-01-27 1992-08-03 Fremgangsmåde til opnåelse af stabiliserede formuleringer med acrylpolymerovertræk til kontrolleret frigivelse

Country Status (22)

Country Link
US (1) US5286493A (da)
EP (1) EP0553392B2 (da)
JP (1) JP3957329B2 (da)
AT (1) ATE184786T1 (da)
AU (1) AU660512B2 (da)
BR (1) BR9204577A (da)
CA (1) CA2074309C (da)
DE (1) DE69230028T3 (da)
DK (1) DK0553392T4 (da)
EG (1) EG20307A (da)
ES (1) ES2141713T5 (da)
GR (1) GR3032106T3 (da)
HK (1) HK1005687A1 (da)
HU (1) HU219350B (da)
IL (1) IL102851A (da)
MX (1) MX9205823A (da)
NO (1) NO309360B1 (da)
NZ (1) NZ245298A (da)
PL (1) PL171376B1 (da)
RU (1) RU2127587C1 (da)
SG (1) SG44698A1 (da)
ZA (1) ZA925687B (da)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
DK0590060T3 (da) * 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) * 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
EP0647448A1 (en) * 1993-10-07 1995-04-12 Euroceltique S.A. Orally administrable opioid formulations having extended duration of effect
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
WO1998001117A1 (en) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
PT951280E (pt) * 1996-10-03 2004-05-31 Hermes Biosciences Inc Microparticulas hidrofilicas e metodos para a sua preparacao
CA2270975C (en) 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
KR100417490B1 (ko) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
DE19808634A1 (de) * 1998-02-24 1999-08-26 Schering Ag Mantel für eine pharmazeutische Zusammensetzung
US7354596B1 (en) 1998-05-01 2008-04-08 3M Innovative Properties Company Anti-microbial agent delivery system
US6471975B1 (en) 1998-05-01 2002-10-29 3M Innovative Properties Company Microspheres as a delivery vehicle for bio-active agents useful in agricultural applications
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
FR2794646B1 (fr) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
IN191239B (da) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US7030097B1 (en) * 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
CA2382577C (en) * 1999-08-27 2008-01-22 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
IL143375A0 (en) * 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20130010512A (ko) * 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
AU776904B2 (en) 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
ATE405264T1 (de) 2000-02-08 2008-09-15 Euro Celtique Sa Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
KR100960200B1 (ko) * 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20040172169A1 (en) * 2001-03-02 2004-09-02 Curtis Wright Method and apparatus for compouding individualized dosege forms
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CA2449519A1 (en) * 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
JP4504013B2 (ja) 2001-08-06 2010-07-14 ユーロ−セルティーク エス．エイ． 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
DE20308437U1 (de) * 2002-04-05 2003-11-13 Euroceltique S.A., Luxemburg/Luxembourg Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
MXPA05000232A (es) 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
DE60335426D1 (de) 2002-08-15 2011-01-27 Euro Celtique Sa Pharmazeutische Zusammensetzungen enthaltend einen Opioidantagonisten
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
EP2422775A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
AU2003295846A1 (en) * 2002-11-26 2004-06-18 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
PL1663229T3 (pl) 2003-09-25 2010-09-30 Euro Celtique Sa Farmaceutyczne kombinacje hydrokodonu i naltreksonu
NZ586198A (en) * 2003-09-26 2011-12-22 Alza Corp Oros push-stick sustained release dosage forms for controlled delivery of active agents
EP1708684A2 (en) 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
KR20120106757A (ko) * 2003-09-26 2012-09-26 알자 코포레이션 오피오이드 및 비오피오이드 진통제의 제어 방출 제제
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
CA2548917C (en) 2003-12-11 2014-09-23 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
DE102004035938A1 (de) * 2004-07-23 2006-02-16 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
AU2005282784B2 (en) * 2004-09-01 2008-06-19 Euro-Celtique S.A. Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
EP1771160A2 (en) * 2005-01-28 2007-04-11 Euroceltique S.A. Alcohol resistant dosage forms
EP2275088B2 (en) * 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Method for producing granules
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US7538163B2 (en) * 2005-03-24 2009-05-26 Medtronic, Inc. Modification of thermoplastic polymers
CA2616204C (en) * 2005-09-09 2015-12-01 Labopharm Inc. Sustained drug release composition
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
JP2009526096A (ja) * 2006-02-07 2009-07-16 エフ エム シー コーポレーション 徐放性被覆をつくるためのコーティング方法
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
BRPI0709606B8 (pt) 2006-03-16 2021-05-25 Tris Pharma Inc suspensão líquida administrável oralmente com características de liberação modificada
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
AU2007280470B2 (en) * 2006-08-04 2013-03-14 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
AU2008286914B2 (en) * 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
JP2008024708A (ja) * 2007-08-20 2008-02-07 Euro-Celtique Sa アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法
EP2057984B1 (de) 2007-11-09 2010-01-20 Acino Pharma AG Retardtabletten mit Hydromorphon
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
BRPI0919249B1 (pt) 2008-09-25 2017-12-19 Isp Investments Inc. Coating composition, method for coating solids and coated product
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
US8811578B2 (en) * 2009-03-23 2014-08-19 Telemanager Technologies, Inc. System and method for providing local interactive voice response services
DE102009034308A1 (de) * 2009-07-21 2011-02-03 Winkelmann, Wolfgang, Dr. Medizinisches Präparat zur Behandlung von entzündlichen Prozessen
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
CN102018962B (zh) * 2010-07-16 2013-11-06 钟术光 在控释制剂中的聚合物增强剂
CN101987083B (zh) * 2010-07-16 2012-12-12 钟术光 一种控释制剂特别是零级释放的控释制剂制备方法
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
ES2444591T3 (es) 2010-10-28 2014-02-25 Acino Pharma Ag Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
WO2012080833A2 (en) 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
PE20181177A1 (es) 2010-12-22 2018-07-20 Purdue Pharma Lp Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
JP5146859B2 (ja) * 2011-07-11 2013-02-20 ユーロ−セルティーク エス．エイ． アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法
CA3120681C (en) 2012-04-17 2024-05-28 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
SG11201407988UA (en) 2012-07-16 2015-01-29 Rhodes Technologies Process for improved opioid synthesis
TWI588147B (zh) 2012-07-16 2017-06-21 羅德科技公司 改良之類鴉片合成方法
EA201500742A1 (ru) 2013-02-05 2015-12-30 Пердью Фарма Л.П. Защищенные от нецелевого использования фармацевтические композиции
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
BR112016002079A2 (pt) 2013-08-02 2017-09-05 Johnson Matthey Plc Processo para preparação de um aditivo ácido de oximorfona, solução aquosa de aditivo ácido de oximorfona, aditivo ácido de oximorfona sólido, e, alcaloide de oximorfona sólido
CA2937007C (en) 2014-01-15 2018-11-06 Rhodes Technologies Process for improved oxymorphone synthesis
WO2015107471A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxycodone synthesis
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
WO2017049185A1 (en) * 2015-09-17 2017-03-23 Ahmad Syed Taymur Process for protecting an electronic device by selective deposition of polymer coatings
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US20180083662A1 (en) * 2016-09-16 2018-03-22 Syed Taymur Ahmad Process for protecting an electronic device by selective deposition of polymer coatings
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12053464B2 (en) * 2017-10-20 2024-08-06 Purdue Pharma L.P. Pharmaceutical dosage forms
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60166608A (ja) * 1984-02-08 1985-08-29 Japan Atom Energy Res Inst サンドイツチ構造をもつ徐放性複合体およびその製造方法
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation

Also Published As

Publication number Publication date
ATE184786T1 (de) 1999-10-15
AU660512B2 (en) 1995-06-29
RU2127587C1 (ru) 1999-03-20
AU2967992A (en) 1993-07-29
ZA925687B (en) 1993-03-02
ES2141713T5 (es) 2008-05-16
NO924597D0 (no) 1992-11-27
PL297534A1 (en) 1993-10-18
DE69230028T2 (de) 2000-04-13
NZ245298A (en) 1995-07-26
HU66961A (en) 1995-01-30
JP3957329B2 (ja) 2007-08-15
DE69230028D1 (de) 1999-10-28
EP0553392B2 (en) 2007-12-05
NO309360B1 (no) 2001-01-22
NO924597L (no) 1993-07-28
MX9205823A (es) 1993-07-01
DK0553392T3 (da) 2000-03-06
HK1005687A1 (en) 1999-01-22
CA2074309A1 (en) 1993-07-28
EP0553392A1 (en) 1993-08-04
EG20307A (en) 1998-10-31
IL102851A0 (en) 1993-01-31
GR3032106T3 (en) 2000-03-31
DE69230028T3 (de) 2008-05-21
PL171376B1 (pl) 1997-04-30
CA2074309C (en) 1999-11-23
HU219350B (en) 2001-03-28
EP0553392B1 (en) 1999-09-22
SG44698A1 (en) 1997-12-19
JPH05201856A (ja) 1993-08-10
BR9204577A (pt) 1993-08-03
HU9300083D0 (en) 1993-04-28
ES2141713T3 (es) 2000-04-01
IL102851A (en) 1997-06-10
US5286493A (en) 1994-02-15

Similar Documents

Publication Publication Date Title
DK0553392T4 (da) Fremgangsmåde til opnåelse af stabiliserede formuleringer med acrylpolymerovertræk til kontrolleret frigivelse
BR9202982A (pt) Processo para obter uma formulacao estabilizada de liberacao controlada,forma de dosagem solida e processo para estabilizar um substrato
RU92004344A (ru) Устойчивые лекарственные формы с регулируемым выделением, имеющие акриловые полимерные покрытия, и способ их получения
FI906344A (fi) Kontrollerat frigoerande farmaceutiskt preparat.
CA2077572A1 (en) Method of and apparatus for stabilizing shapes of objects, such as optical elements, as well as exposure apparatus using same and method of manufacturing semiconductr devices
ATE241341T1 (de) Stabilisierte pharmazeutische zusammensetzung
DK0575930T3 (da) Fremgangsmåde til fremstilling af faste farmaceutiske retardformer
BR8206107A (pt) Processo para preparacao de uma composicao de resina sintetica formadora de filme termicamente curavel,e de uma composicao aquosa de revestimento,e para revestimento de um substrato de metal
NO880230L (no) Peroralt preparat med forsinket frigjoering.
NO881605D0 (no) Fremgangsmaate til fremstilling av en ekstruderingsdyse for produksjon av plastgjenstander med regulert veggtykkelse.
JPS53123942A (en) Production of optical fibers